[A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
Park
Sang Hoon
SH
Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul, Korea.
Jeen
Yoon Tae
YT
Chun
Hwang Rae
HR
Kim
Dong Il
DI
Baeck
Chang Won
CW
Kim
Yong Sik
YS
Chun
Hoon Jai
HJ
Lee
Hong Sik
HS
Um
Soon Ho
SH
Choi
Jai Hyun
JH
Kim
Chang Duck
CD
Ryu
Ho Sang
HS
Hyun
Jin Hai
JH
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab